Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
Frau J, Saccà F, Signori A, Baroncini D, Fenu G, Annovazzi P, Capobianco M, Signoriello E, Laroni A, La Gioia S, Sartori A, Maniscalco GT, Bonavita S, Clerico M, Russo CV, Gallo A, Lapucci C, Carotenuto A, Sormani MP, Cocco E; i-MuST study group.
Frau J, et al. Among authors: lapucci c.
J Neurol. 2019 Oct;266(10):2440-2446. doi: 10.1007/s00415-019-09424-8. Epub 2019 Jun 17.
J Neurol. 2019.
PMID: 31209573